Literature DB >> 16258088

Randomized trial of prevention of catheter-related bloodstream infection by continuous infusion of low-dose unfractionated heparin in patients with hematologic and oncologic disease.

Abderrahman Abdelkefi1, Lamia Torjman, Saloua Ladeb, Tarek Ben Othman, Wafa Achour, Amel Lakhal, Mohamed Hsairi, Leila Kammoun, Assia Ben Hassen, Abdeladhim Ben Abdeladhim.   

Abstract

PURPOSE: Infection is a serious complication of central venous catheters in immunocompromised patients. Catheter-related infection may be caused by fibrin deposition associated with catheters. Interventions designed to decrease fibrin deposition have the potential to reduce catheter-related infections. The purpose of this study was to evaluate the role of low-dose unfractionated heparin in preventing catheter-related bloodstream infection in patients with hemato-oncological disease. PATIENTS AND METHODS: This study was a randomized, controlled trial in which patients with nontunneled catheters were randomly assigned to receive either intravenous unfractionated heparin (continuous infusion of 100 U/kg per day) or 50 mL/day of normal saline solution as a continuous infusion (control group). Heparin was continued until the day of discharge. Catheter-related bloodstream infection was defined according to Infectious Disease Society of America guidelines.
RESULTS: Two hundred and eight patients were randomly assigned. Four patients were excluded after assignment. Ultimately, 204 patients were analyzed. Catheter-related bloodstream infection occurred in 6.8% (7 of 102 catheters) of those in the heparin group (2.5 events per 1,000 days) and in 16.6% (17 of 102 catheters) of those in the control group (6.4 events per 1,000 days) (P = .03). No other risk factors were found for the development of catheter-related bloodstream infection. Four and five patients experienced severe bleeding in the heparin and control groups, respectively (P = .2). We did not observe heparin-induced thrombocytopenia.
CONCLUSION: The use of continuous infusion of low-dose unfractionated heparin (100 U/kg per day) can be a practical and economical approach to the prevention of catheter-related bloodstream infection in patients with hemato-oncological disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16258088     DOI: 10.1200/JCO.2004.00.9787

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  13 in total

Review 1.  Catheter-related infections in pediatric patients with cancer.

Authors:  V Cecinati; L Brescia; L Tagliaferri; P Giordano; S Esposito
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-06-03       Impact factor: 3.267

2.  Guidelines for the prevention of intravascular catheter-related infections.

Authors:  Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

3.  epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England.

Authors:  H P Loveday; J A Wilson; R J Pratt; M Golsorkhi; A Tingle; A Bak; J Browne; J Prieto; M Wilcox
Journal:  J Hosp Infect       Date:  2014-01       Impact factor: 3.926

Review 4.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis
Journal:  Cochrane Database Syst Rev       Date:  2022-07-18

Review 5.  Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer.

Authors:  Ceder van den Bosch; Job van Woensel; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2021-10-07

6.  The role of tissue plasminogen activator use and systemic hypercoagulability in central line-associated bloodstream infections.

Authors:  Kinna Thakarar; Matthew Collins; Lana Kwong; Carol Sulis; Cathy Korn; Nahid Bhadelia
Journal:  Am J Infect Control       Date:  2014-02-20       Impact factor: 2.918

7.  Concentrated citrate locking in order to reduce the long-term complications of central venous catheters: a randomized controlled trial in patients with hematological malignancies.

Authors:  R S Boersma; K S Jie; A C Voogd; K Hamulyak; A Verbon; H C Schouten
Journal:  Support Care Cancer       Date:  2014-06-20       Impact factor: 3.603

8.  New materials and devices for preventing catheter-related infections.

Authors:  Jean-François Timsit; Yohann Dubois; Clémence Minet; Agnès Bonadona; Maxime Lugosi; Claire Ara-Somohano; Rebecca Hamidfar-Roy; Carole Schwebel
Journal:  Ann Intensive Care       Date:  2011-08-18       Impact factor: 6.925

9.  Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome.

Authors:  Mahmut Yeral; Can Boğa; Levent Oğuzkurt; Hikmet Eda Alışkan; Hakan Özdoğu; Yusuf Ziya Demiroğlu
Journal:  Turk J Haematol       Date:  2015-03-05       Impact factor: 1.831

Review 10.  Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults.

Authors:  Eduardo López-Briz; Vicente Ruiz Garcia; Juan B Cabello; Sylvia Bort-Martí; Rafael Carbonell Sanchis; Amanda Burls
Journal:  Cochrane Database Syst Rev       Date:  2018-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.